Nephroplus Designated Persons Submit Trading Plans for August 2026
Nephrocare Health Services Limited announced approved trading plans from Group CEO Rohit Singh and CEO India & Nepal Sukaran Singh Saluja. Singh plans to sell 30,000 shares and Saluja plans to sell 60,000 shares between December 7-11, 2026, at a minimum price of ₹700 per share.
Trading plans are a standard regulatory requirement for designated persons and outline future potential trades. The approved plans specify sale of shares within a price range and a defined future period, which is a normal part of corporate governance and insider trading regulations, and does not indicate any significant immediate impact on the company's operations or market.
The announcement pertains to routine regulatory filings regarding trading plans by designated persons, which is a standard procedure under SEBI regulations. It does not contain information that inherently suggests a positive or negative outlook for the company's performance or stock.
Nephrocare Health Services Limited has received and approved Trading Plans from two of its designated persons, Mr. Rohit Singh, Group Chief Executive Officer, and Mr. Sukaran Singh Saluja, CEO - India and Nepal Business. These plans, submitted under Regulation 5(5) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, outline the intention to trade in the company's equity shares.
Mr. Rohit Singh's trading plan involves the sale of 30,000 equity shares between December 7, 2026, and December 11, 2026. The sale is subject to a minimum price of ₹700.00 per equity share. Mr. Sukaran Singh Saluja's plan details the sale of 60,000 equity shares during the same period, also with a minimum price of ₹700.00 per equity share. Both individuals have confirmed adherence to the cool-off period and other SEBI PIT Regulations, ensuring the trades will be executed within the approved limits and in compliance with the company's code of conduct.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under insider trading. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.